Centiva Capital LP Takes Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Centiva Capital LP acquired a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 13,450 shares of the biopharmaceutical company's stock, valued at approximately $643,000.

A number of other institutional investors have also recently bought and sold shares of HALO. Smartleaf Asset Management LLC raised its holdings in Halozyme Therapeutics by 29.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock valued at $42,000 after buying an additional 197 shares in the last quarter. Louisiana State Employees Retirement System increased its stake in shares of Halozyme Therapeutics by 0.6% in the fourth quarter. Louisiana State Employees Retirement System now owns 35,300 shares of the biopharmaceutical company's stock worth $1,688,000 after purchasing an additional 200 shares during the period. Baird Financial Group Inc. increased its stake in shares of Halozyme Therapeutics by 2.0% in the fourth quarter. Baird Financial Group Inc. now owns 11,119 shares of the biopharmaceutical company's stock worth $532,000 after purchasing an additional 221 shares during the period. CreativeOne Wealth LLC increased its stake in shares of Halozyme Therapeutics by 1.6% in the fourth quarter. CreativeOne Wealth LLC now owns 18,383 shares of the biopharmaceutical company's stock worth $879,000 after purchasing an additional 294 shares during the period. Finally, State of New Jersey Common Pension Fund D increased its stake in shares of Halozyme Therapeutics by 0.6% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 47,663 shares of the biopharmaceutical company's stock worth $2,279,000 after purchasing an additional 302 shares during the period. Institutional investors and hedge funds own 97.79% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on HALO shares. Benchmark lowered Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, May 7th. HC Wainwright reiterated a "buy" rating and issued a $72.00 price objective on shares of Halozyme Therapeutics in a research note on Friday, April 25th. Leerink Partners lowered Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 price objective on the stock. in a research note on Tuesday. Morgan Stanley lowered Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and lowered their price target for the company from $73.00 to $62.00 in a research note on Wednesday. Finally, JPMorgan Chase & Co. boosted their price target on Halozyme Therapeutics from $55.00 to $58.00 and gave the company a "neutral" rating in a research note on Monday, April 21st. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $61.90.

Halozyme Therapeutics Price Performance

Shares of HALO stock traded down $2.28 during trading hours on Wednesday, hitting $47.95. The company had a trading volume of 3,964,708 shares, compared to its average volume of 1,757,428. Halozyme Therapeutics, Inc. has a 12 month low of $42.01 and a 12 month high of $70.50. The firm has a market capitalization of $5.91 billion, a price-to-earnings ratio of 13.98, a PEG ratio of 0.42 and a beta of 1.26. The firm's fifty day moving average is $61.39 and its 200 day moving average is $55.96. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share for the quarter, beating the consensus estimate of $0.98 by $0.13. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The company had revenue of $264.86 million for the quarter, compared to analyst estimates of $231.21 million. During the same period in the prior year, the company posted $0.79 EPS. The company's revenue was up 35.2% compared to the same quarter last year. On average, sell-side analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Jeffrey William Henderson sold 5,000 shares of the firm's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $58.69, for a total transaction of $293,450.00. Following the sale, the director now owns 33,611 shares of the company's stock, valued at approximately $1,972,629.59. This trade represents a 12.95% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Michael J. Labarre sold 1,697 shares of the stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $58.28, for a total value of $98,901.16. Following the transaction, the senior vice president now owns 173,756 shares of the company's stock, valued at approximately $10,126,499.68. This trade represents a 0.97% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 21,697 shares of company stock valued at $1,276,552. 2.40% of the stock is currently owned by corporate insiders.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.